The PIK3CA Mutation in Advanced Breast Cancer Chemoresistance and Recurrence
Movchan Oleksii Volodimirovich 1*, Smolanka Ivan Ivanovich 1, Lyashenko Andriy Oleksandrovich 1, Loboda Anton Dmitrovich 1, Dosenko Irina Viktorivna 1, Dosenko Irina Viktorivna 1, Ivankova Oksana Mykolaivna 1
Journal of Angiotherapy 8(4) 1-5 https://doi.org/10.25163/angiotherapy.849552
Submitted: 02 March 2024 Revised: 03 April 2024 Published: 06 April 2024
This study demonstrated PIK3CA mutations' role in chemoresistance and recurrence informs targeted therapies, potentially improving outcomes for advanced breast cancer patients.
Abstract
Background: The molecular mechanisms facilitating the resurgence of critical breast tumor cells and their potential to engender malignant lesions remain elusive. Several carcinogenic pathways contribute to the progression, chemoresistance, and recurrence of primary breast cancer (BC), among which is the PIK3CA mutation within the PI3K-AKT-mTOR pathway. Drug resistance poses a significant challenge to effective therapy for advanced breast cancer (ABC). This study aimed to assess the PIK3CA mutation as a diagnostic marker for disease prognosis and the prediction of treatment response. Methods: Ninety patients with advanced resistant BC were stratified into two groups: 1) 45 patients with PIK3CA mutation; 2) 45 patients with 'wild-type' PIK3CA. Patient data were collected regarding overall survival and relapse-free status. All patients received comprehensive treatment according to generally accepted standards for their respective subtypes. Results: Seventy percent of lesions associated with chemoresistance and recurrence exhibited high levels of the PIK3CA mutation. Among PIK3CA mutation lesions, 40% were HER2-positive. Analysis of immunohistochemistry data from 30 patients and matched pairings revealed that 18 patients with HER2-positive/PIK3CA mutation exhibited high expression of acquired hormone status, with 35% of patients presenting with ER-negative disease. Conclusions: Women with HER2-positive/PIK3CA mutation lesions demonstrated a threefold higher frequency of subsequent hormone status compared to those with HER2-negative/PIK3CA wild-type lesions. HER2-positive/PIK3CA mutation was associated with ER-negative disease, chemoresistance, and recurrence. These findings underscore the importance of evaluating the protein expression of HER2 and PIK3CA mutations in ABC patients post-diagnosis and intensifying anti-relapse therapy.
Keywords: PIK3CA Mutation, Advanced breast cancer, Chemoresistance, Disease recurrence.
References
Alqahtani, A., Ayesh, H. S. K., & Halawani, H. (2019). PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis. Cancers (Basel), 12(1), 93. Link
Ben Rekaya, M., Sassi, F., Saied, E., Bel Haj Kacem, L., & Mansouri, N. (2023). PIK3CA mutations in breast cancer: A Tunisian series. PLoS One, 18(5), e0285413. Link
Cho, Y., Ko, S., Suh, Y., Kim, S., & Park, J. et al. (2022). PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. Curr Oncol, 29(5), 2895-2908. Link
Dudas, J., Ladanyi, A., Ingruber, J., Steinbichler, T., & Riechelmann, H. (2020). Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. Cells, 9(2), 428. Link
Elshazly, A., & Gewirtz, D. (2022). An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. Cancer Drug Resist, 5(2), 472-486. Link
Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., & Nicolini, A. (2022). Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci, 23(3), 1665. Link
Fultang, N., Chakraborty, M., & Peethambaran, B. (2021). Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist, 4(2), 321-342. Link
Gupta, P., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019). Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Cell Stem Cell, 24(1), 65–78. Link
Hu, H., Zhu, J., Zhong, Y., Geng, R., Ji, Y., Guan, Q., Hong, C., Wei, Y., Min, N., Qi, A., Zhang, Y., & Li, X. (2021). PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med, 9(5), 410. Link
Kaboli, P., Imani, S., Jomhori, M., & Ling, K. (2021). Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. Am J Cancer Res, 11(10), 5155-5183. Link
Kim, J., Lim, A., You, J., Lee, J., & Song, S. et al. (2023). PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients. Cancer Res Treat, 55(2), 531-541. Link
Lytle, N., Barber, A. G., & Reya, T. (2018). Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer, 18(11), 669–680. Link
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., & Fazi, F. (2023). Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Mol Aspects Med, 93, 101205. Link
Narayan, P., Prowell, T., Gao, J., Fernandes, L., Li, E., et al. (2021). FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clin Cancer Res, 27(7), 1842–1849. Link
Nedeljkovic, M., & Damjanovic, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells, 8(9), 957. Link
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022). PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol, 12, 819128. Link
Rascio, F., Spadaccino, F., Rocchetti, M., Castellano, G., & Stallone, G. (2021). The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers (Basel), 13(16), 3949. Link
Rasti, A., Guimaraes-Young, A., Datko, F., Borges, V., & Aisner, D. (2022). PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol, 6, e2100370. Link
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1). Last Update Posted: November 18, 2023. Link
Testa, U., Castelli, G., & Pelosi, E. (2020). Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med Sci (Basel), 8(1), 18. Link
View Dimensions
View Altmetric
Save
Citation
View
Share